BRAF与MEK抑制剂通过焦亡调控肿瘤免疫微环境
该研究探讨BRAF抑制剂联合MEK抑制剂(BRAFi+MEKi)治疗BRAF V600E/K突变黑色素瘤时,通过诱导焦亡(GSDME切割和HMGB1释放)介导持久的免疫依赖性肿瘤消退,而耐药肿瘤缺乏焦亡标志物且T细胞浸润减少,但对诱导焦亡的化疗敏感。
要点
- BRAFi+MEKi通过GSDME介导焦亡促进HMGB1释放并增强T细胞浸润。
- GSDME缺陷导致HMGB1释放减少、免疫细胞浸润下降且停药后更易复发。
- BRAFi+MEKi耐药肿瘤缺乏焦亡标志物,但对焦亡诱导化疗敏感。
核心结论
- BRAFi+MEKi以免疫介导方式诱导持久的黑色素瘤消退。
- BRAFi+MEKi诱导的焦亡参与抗肿瘤免疫应答。
- 耐药黑色素瘤对诱导焦亡的化疗敏感,提示 salvage 治疗策略。
研究设计与样本
- 研究使用黑色素瘤模型探讨BRAFi+MEKi与肿瘤免疫微环境的关系。
主要发现
- BRAFi+MEKi促进GSDME切割和HMGB1释放,后者为焦亡标志。
- GSDME缺陷黑色素瘤中HMGB1释放缺陷,肿瘤相关T细胞和活化树突状细胞浸润减少。
- GSDME缺陷黑色素瘤在停药后更频繁出现肿瘤再生长。
- BRAFi+MEKi耐药肿瘤缺乏焦亡标志物且瘤内T细胞浸润减少。
- 耐药肿瘤对诱导焦亡的化疗敏感。
临床怎么用
- BRAFi+MEKi治疗黑色素瘤时需关注焦亡标志物及免疫细胞浸润。
- 对BRAFi+MEKi耐药黑色素瘤可考虑诱导焦亡的化疗作为挽救治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + MEKi caused durable melanoma regression in an immune-mediated manner. BRAFi + MEKi treatment promoted cleavage of gasdermin E (GSDME) and release of HMGB1, markers of pyroptotic cell death. GSDME-deficient melanoma showed defective HMGB1 release, reduced tumor-associated T cell and activated dendritic cell infiltrates in response to BRAFi + MEKi, and more frequent tumor regrowth after drug removal. Importantly, BRAFi + MEKi-resistant disease lacked pyroptosis markers and showed decreased intratumoral T-cell infiltration but was sensitive to pyroptosis-inducing chemotherapy. These data implicate BRAFi + MEKi-induced pyroptosis in antitumor immune responses and highlight new therapeutic strategies for resistant melanoma. SIGNIFICANCE: Targeted inhibitors and immune checkpoint agents have advanced the care of patients with melanoma; however, detailed knowledge of the intersection between these two research areas is lacking. We describe a molecular mechanism of targeted inhibitor regulation of an immune-stimulatory form of cell death and provide a proof-of-principle salvage therapy concept for inhibitor-resistant melanoma.See related commentary by Smalley, p. 176.This article is highlighted in the In This Issue feature, p. 161.
引用
- Erkes DA, Cai W, Sanchez IM, et al. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis. Cancer Discov. 2019. PMID: 31796433. doi:10.1158/2159-8290.CD-19-0672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。